Gene therapy: retinal & CNS degenerative pathologies and mitochondrial disease. Lead, GS010, Ph 3 for Leber Hereditary Optic Neuropathy (LHON). REVERSE Ph 3 topline data announced Apr 2018, RESCUE Ph 3 72-week data reported April 2019. Third Ph 3, REFLECT, exp 2020. Filing for MAA exp Q4 2019 in EU and 2020 in US. Pipeline concomitant program, GS030: optogenetic combo drug + enhancing goggle device: non-syndromic retinitis pigmentosa. Optogenetic program and targeted disease immediately transferable to dry AMD. Platform combines mono-genetic therapy-based approach w core technology platform and proprietary Mitochondrial Targeting Sequence.
74, rue du Faubourg Saint-Antoine
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
GenSight Biologics KOL Event New York 2019
May 23, 2019
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by